Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Cutaneous immune-related adverse events (cirAEs) occur in up to 40% of immune checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival remains unclear.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Am Acad Dermatol

Title: Journal of the American Academy of Dermatology

Publisher: Elsevier BV

ISSN (Electronic): 1097-6787

ISSN (Print): 0190-9622

Publication date (Electronic): May 2023

Volume: 88

Issue: 5

Affiliations

[1 ] Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts.

[2 ] Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

[3 ] Division of Oncology and Hematology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

[4 ] Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts.

[5 ] Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Center for Cancer Immunology and Cutaneous Biology Research Center, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

[6 ] Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

[7 ] Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts.

[8 ] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

[9 ] Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

[10 ] Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: ysemenov@mgh.harvard.edu.

Article

Mid ID: NIHMS1902791 Publisher Item ID: S0190-9622(23)00153-6

DOI: 10.1016/j.jaad.2022.12.048

PMC ID: 10283025

PubMed ID: 36736626

SO-VID: 01f94af0-187e-4c6a-8830-52f5dc7a17fb

History

Keywords: oncology,cutaneous adverse reactions,immune checkpoint inhibitor,immune-related adverse events,immunotherapy,melanoma,mortality,skin toxicity

Data availability:

Keywords: oncology, cutaneous adverse reactions, immune checkpoint inhibitor, immune-related adverse events, immunotherapy, melanoma, mortality, skin toxicity

Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.

Read this article at

Abstract

Related collections

Cancer Immunotherapy

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 41

Cited by 9